Re-evaluating the impact of prenatal low-dose aspirin on child neurodevelopment

Area of Science:

• Obstetrics and Gynecology
• Neurodevelopmental Pediatrics
• Pharmacology

Background:

• Clinical guidelines recommend prophylactic low-dose aspirin from 12 weeks gestation for high-risk preeclampsia patients.
• Aspirin crosses the placenta, potentially affecting maternal and fetal physiology.
• The impact of prenatal low-dose aspirin exposure on child neurodevelopment remains unclear.

Purpose of the Study:

• To review the pharmacokinetic properties of aspirin in maternal and fetal circulation.
• To discuss potential mechanisms linking prenatal aspirin exposure to child neurodevelopment.
• To evaluate current evidence on the safety and potential effects of prenatal low-dose aspirin on neurodevelopment.

Main Methods:

• Literature review of pharmacokinetic data.
• Analysis of existing observational and experimental studies.
• Discussion of proposed biological pathways.

Main Results:

• Prenatal low-dose aspirin exposure is not associated with adverse neurodevelopmental outcomes.
• Some evidence suggests potential neurodevelopmental benefits.
• Pharmacokinetic data highlights placental transfer and potential fetal exposure.

Conclusions:

• Current evidence indicates prenatal low-dose aspirin is likely safe for child neurodevelopment.
• Further research, including observational and experimental studies, is necessary to confirm these findings and elucidate underlying mechanisms.
• Understanding the long-term neurodevelopmental effects requires continued investigation.